The University of Oxford is studying a nasal spray version of the Oxford-AstraZeneca COVID-19 vaccine among 30 young, healthy volunteers, and will assess the induced immune response, safety and any ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Researchers at Oxford announced today that a nasal spray version of ...

AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. The AstraZeneca-funded phase 1 trial ...

Since the coronavirus enters the body through the nose, researchers have figured a nasal spray may be one way to defend against its spread. But developing an effective point-of-entry vaccine can be ...

Oxford University is reportedly ready to begin testing a nasal spray version of the Covid-19 vaccine it developed with pharmaceutical giant AstraZeneca, according to documents seen by the Financial ...

A STUDY investigating the delivery of the Covid vaccine through a nasal spray is being carried out by Oxford University. Thirty volunteers aged between 18-40 from the Oxford region, are taking part in ...

Since early in the pandemic, researchers have been working to develop a vaccine for SARS-CoV-2 that could be administered in the form of a nasal spray, as such a spray would be simpler to administer ...

A trial is reportedly set to begin to study delivering Oxford and AstraZeneca's COVID-19 vaccine as a nasal spray. Oxford is seeking participants for a trial to deliver the vaccine it developed with ...

* UNIVERSITY OF OXFORD SAYS LAUNCHING STUDY INVESTIGATING THE DELIVERY OF THE CHADOX1 NCOV-19 CORONAVIRUS VACCINE USING A NASAL SPRAY * OXFORD - VACCINE WILL BE DELIVERED USING AN INTRANASAL SPRAY ...

The nasal version of the Oxford/AstraZeneca COVID-19 vaccine has failed in an early-stage trial, setting back the hopes of the needle-free alternative often hailed as the next generation of vaccines.

The drive to develop a nasal spray against COVID-19 infection suffered a setback Tuesday after AstraZeneca and Oxford University said a trial produced disappointing results. Only a “minority of ...